Global Late-Stage Oncology Drug Supply, Demand and Key Producers, 2026-2032
The global Late-Stage Oncology Drug market size is expected to reach $ 857596 million by 2032, rising at a market growth of 8.0% CAGR during the forecast period (2026-2032).
Late-Stage Oncology Drug refers to cancer therapeutics that are either already commercialized or have entered late clinical development, typically including Phase III, registrational, submitted, or near-approval oncology drug candidates. These drugs cover a broad range of treatment modalities such as immune checkpoint inhibitors, targeted small-molecule therapies, antibody-drug conjugates, bispecific antibodies, CAR-T and other cell therapies, radioligand therapies, hormone therapies and advanced chemotherapy combinations. Compared with early-stage oncology assets, late-stage oncology drugs usually have clearer clinical efficacy data, defined target indications, mature trial endpoints and higher commercialization visibility, making them a key focus for pharmaceutical companies, hospitals, payers and investors.
The demand for Late-Stage Oncology Drugs is driven by the rising global cancer burden, longer patient survival, earlier diagnosis, biomarker-guided treatment and continuous expansion of therapy lines across lung cancer, breast cancer, hematologic malignancies, gastrointestinal tumors, prostate cancer and rare cancers. Business opportunities are concentrated in high-value therapeutic areas such as PD-1/PD-L1 combination regimens, antibody-drug conjugates, bispecific antibodies, cell therapies, radiopharmaceuticals and precision targeted therapies, especially where products can improve survival, reduce toxicity or address drug resistance. In addition, emerging markets such as China, Southeast Asia, Latin America and the Middle East are becoming important growth regions as oncology diagnosis capacity, reimbursement coverage and access to innovative medicines improve. For pharmaceutical companies, opportunities lie not only in original drug development, but also in lifecycle management, indication expansion, companion diagnostics, real-world evidence generation, licensing partnerships and global commercialization of differentiated late-stage oncology assets.
This report studies the global Late-Stage Oncology Drug demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Late-Stage Oncology Drug, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Late-Stage Oncology Drug that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Late-Stage Oncology Drug total market, 2021-2032, (USD Million)
Global Late-Stage Oncology Drug total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Late-Stage Oncology Drug total market, key domestic companies, and share, (USD Million)
Global Late-Stage Oncology Drug revenue by player, revenue and market share 2021-2026, (USD Million)
Global Late-Stage Oncology Drug total market by Therapeutic Modality, CAGR, 2021-2032, (USD Million)
Global Late-Stage Oncology Drug total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Late-Stage Oncology Drug market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Merck & Co., Bristol Myers Squibb, Pfizer, Novartis, AstraZeneca, Johnson & Johnson Innovative Medicine, Eli Lilly and Company, Sanofi, AbbVie, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Late-Stage Oncology Drug market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Therapeutic Modality, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Late-Stage Oncology Drug Market, By Region:
1. How big is the global Late-Stage Oncology Drug market?
2. What is the demand of the global Late-Stage Oncology Drug market?
3. What is the year over year growth of the global Late-Stage Oncology Drug market?
4. What is the total value of the global Late-Stage Oncology Drug market?
5. Who are the Major Players in the global Late-Stage Oncology Drug market?
6. What are the growth factors driving the market demand?
Late-Stage Oncology Drug refers to cancer therapeutics that are either already commercialized or have entered late clinical development, typically including Phase III, registrational, submitted, or near-approval oncology drug candidates. These drugs cover a broad range of treatment modalities such as immune checkpoint inhibitors, targeted small-molecule therapies, antibody-drug conjugates, bispecific antibodies, CAR-T and other cell therapies, radioligand therapies, hormone therapies and advanced chemotherapy combinations. Compared with early-stage oncology assets, late-stage oncology drugs usually have clearer clinical efficacy data, defined target indications, mature trial endpoints and higher commercialization visibility, making them a key focus for pharmaceutical companies, hospitals, payers and investors.
The demand for Late-Stage Oncology Drugs is driven by the rising global cancer burden, longer patient survival, earlier diagnosis, biomarker-guided treatment and continuous expansion of therapy lines across lung cancer, breast cancer, hematologic malignancies, gastrointestinal tumors, prostate cancer and rare cancers. Business opportunities are concentrated in high-value therapeutic areas such as PD-1/PD-L1 combination regimens, antibody-drug conjugates, bispecific antibodies, cell therapies, radiopharmaceuticals and precision targeted therapies, especially where products can improve survival, reduce toxicity or address drug resistance. In addition, emerging markets such as China, Southeast Asia, Latin America and the Middle East are becoming important growth regions as oncology diagnosis capacity, reimbursement coverage and access to innovative medicines improve. For pharmaceutical companies, opportunities lie not only in original drug development, but also in lifecycle management, indication expansion, companion diagnostics, real-world evidence generation, licensing partnerships and global commercialization of differentiated late-stage oncology assets.
This report studies the global Late-Stage Oncology Drug demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Late-Stage Oncology Drug, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Late-Stage Oncology Drug that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Late-Stage Oncology Drug total market, 2021-2032, (USD Million)
Global Late-Stage Oncology Drug total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Late-Stage Oncology Drug total market, key domestic companies, and share, (USD Million)
Global Late-Stage Oncology Drug revenue by player, revenue and market share 2021-2026, (USD Million)
Global Late-Stage Oncology Drug total market by Therapeutic Modality, CAGR, 2021-2032, (USD Million)
Global Late-Stage Oncology Drug total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Late-Stage Oncology Drug market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Merck & Co., Bristol Myers Squibb, Pfizer, Novartis, AstraZeneca, Johnson & Johnson Innovative Medicine, Eli Lilly and Company, Sanofi, AbbVie, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Late-Stage Oncology Drug market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Therapeutic Modality, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Late-Stage Oncology Drug Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Small-Molecule Targeted Oncology Drugs
- Monoclonal Antibody Oncology Drugs
- Antibody-Drug Conjugates
- Bispecific Antibody Oncology Drugs
- Cell Therapy Oncology Drugs
- Radioligand Oncology Drugs
- Conventional Chemotherapy And Hormone Therapy Drugs
- Others
- Low-Priced Oncology Drugs: Below US$20,000 / Patient / Year
- Mid-Priced Oncology Drugs: US$20,000?80,000 / Patient / Year
- High-Priced Oncology Drugs: US$80,000?200,000 / Patient / Year
- Ultra-High-Priced Oncology Drugs: Above US$200,000 / Patient / Year
- Phase III Oncology Drugs
- Registrational Oncology Drugs
- Others
- Lung Cancer
- Breast Cancer
- Gastrointestinal Cancers
- Genitourinary Cancers
- Hematologic Malignancies
- Gynecologic Cancers
- Skin Cancer
- Others
- Roche
- Merck & Co.
- Bristol Myers Squibb
- Pfizer
- Novartis
- AstraZeneca
- Johnson & Johnson Innovative Medicine
- Eli Lilly and Company
- Sanofi
- AbbVie
- GSK
- Amgen
- Daiichi Sankyo Group
- Takeda Pharmaceutical
- Astellas Pharma
- Eisai
- Taiho Pharmaceutical
- Ono Pharmaceutical
- Gilead Sciences
- Regeneron Pharmaceuticals
- Exelixis
- Incyte
- Ipsen
- AVEO Oncology
- BeOne Medicines
- Jiangsu Hengrui Pharmaceuticals
- Innovent Biologics
- Shanghai Junshi Biosciences
- Akeso Biopharma
- Legend Biotech
- Zai Lab
1. How big is the global Late-Stage Oncology Drug market?
2. What is the demand of the global Late-Stage Oncology Drug market?
3. What is the year over year growth of the global Late-Stage Oncology Drug market?
4. What is the total value of the global Late-Stage Oncology Drug market?
5. Who are the Major Players in the global Late-Stage Oncology Drug market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Late-Stage Oncology Drug Introduction
1.2 World Late-Stage Oncology Drug Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Late-Stage Oncology Drug Total Market by Region (by Headquarter Location)
1.3.1 World Late-Stage Oncology Drug Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Late-Stage Oncology Drug Revenue (2021-2032)
1.3.3 China Based Company Late-Stage Oncology Drug Revenue (2021-2032)
1.3.4 Europe Based Company Late-Stage Oncology Drug Revenue (2021-2032)
1.3.5 Japan Based Company Late-Stage Oncology Drug Revenue (2021-2032)
1.3.6 South Korea Based Company Late-Stage Oncology Drug Revenue (2021-2032)
1.3.7 ASEAN Based Company Late-Stage Oncology Drug Revenue (2021-2032)
1.3.8 India Based Company Late-Stage Oncology Drug Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Late-Stage Oncology Drug Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Late-Stage Oncology Drug Consumption Value (2021-2032)
2.2 World Late-Stage Oncology Drug Consumption Value by Region
2.2.1 World Late-Stage Oncology Drug Consumption Value by Region (2021-2026)
2.2.2 World Late-Stage Oncology Drug Consumption Value Forecast by Region (2027-2032)
2.3 United States Late-Stage Oncology Drug Consumption Value (2021-2032)
2.4 China Late-Stage Oncology Drug Consumption Value (2021-2032)
2.5 Europe Late-Stage Oncology Drug Consumption Value (2021-2032)
2.6 Japan Late-Stage Oncology Drug Consumption Value (2021-2032)
2.7 South Korea Late-Stage Oncology Drug Consumption Value (2021-2032)
2.8 ASEAN Late-Stage Oncology Drug Consumption Value (2021-2032)
2.9 India Late-Stage Oncology Drug Consumption Value (2021-2032)
3 WORLD LATE-STAGE ONCOLOGY DRUG COMPANIES COMPETITIVE ANALYSIS
3.1 World Late-Stage Oncology Drug Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Late-Stage Oncology Drug Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Late-Stage Oncology Drug in 2025
3.2.3 Global Concentration Ratios (CR8) for Late-Stage Oncology Drug in 2025
3.3 Late-Stage Oncology Drug Company Evaluation Quadrant
3.4 Late-Stage Oncology Drug Market: Overall Company Footprint Analysis
3.4.1 Late-Stage Oncology Drug Market: Region Footprint
3.4.2 Late-Stage Oncology Drug Market: Company Product Type Footprint
3.4.3 Late-Stage Oncology Drug Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Late-Stage Oncology Drug Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Late-Stage Oncology Drug Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Late-Stage Oncology Drug Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Late-Stage Oncology Drug Consumption Value Comparison
4.2.1 United States VS China: Late-Stage Oncology Drug Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Late-Stage Oncology Drug Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Late-Stage Oncology Drug Companies and Market Share, 2021-2026
4.3.1 United States Based Late-Stage Oncology Drug Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Late-Stage Oncology Drug Revenue, (2021-2026)
4.4 China Based Companies Late-Stage Oncology Drug Revenue and Market Share, 2021-2026
4.4.1 China Based Late-Stage Oncology Drug Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Late-Stage Oncology Drug Revenue, (2021-2026)
4.5 Rest of World Based Late-Stage Oncology Drug Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Late-Stage Oncology Drug Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Late-Stage Oncology Drug Revenue (2021-2026)
5 MARKET ANALYSIS BY THERAPEUTIC MODALITY
5.1 World Late-Stage Oncology Drug Market Size Overview by Therapeutic Modality: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Therapeutic Modality
5.2.1 Small-Molecule Targeted Oncology Drugs
5.2.2 Monoclonal Antibody Oncology Drugs
5.2.3 Antibody-Drug Conjugates
5.2.4 Bispecific Antibody Oncology Drugs
5.2.5 Cell Therapy Oncology Drugs
5.2.6 Radioligand Oncology Drugs
5.2.7 Conventional Chemotherapy And Hormone Therapy Drugs
5.2.8 Others
5.3 Market Segment by Therapeutic Modality
5.3.1 World Late-Stage Oncology Drug Market Size by Therapeutic Modality (2021-2026)
5.3.2 World Late-Stage Oncology Drug Market Size by Therapeutic Modality (2027-2032)
5.3.3 World Late-Stage Oncology Drug Market Size Market Share by Therapeutic Modality (2027-2032)
6 MARKET ANALYSIS BY ANNUAL TREATMENT COST PER PATIENT
6.1 World Late-Stage Oncology Drug Market Size Overview by Annual Treatment Cost Per Patient: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Annual Treatment Cost Per Patient
6.2.1 Low-Priced Oncology Drugs: Below US$20,000 / Patient / Year
6.2.2 Mid-Priced Oncology Drugs: US$20,000?80,000 / Patient / Year
6.2.3 High-Priced Oncology Drugs: US$80,000?200,000 / Patient / Year
6.2.4 Ultra-High-Priced Oncology Drugs: Above US$200,000 / Patient / Year
6.3 Market Segment by Annual Treatment Cost Per Patient
6.3.1 World Late-Stage Oncology Drug Market Size by Annual Treatment Cost Per Patient (2021-2026)
6.3.2 World Late-Stage Oncology Drug Market Size by Annual Treatment Cost Per Patient (2027-2032)
6.3.3 World Late-Stage Oncology Drug Market Size Market Share by Annual Treatment Cost Per Patient (2027-2032)
7 MARKET ANALYSIS BY CLINICAL DEVELOPMENT STATUS
7.1 World Late-Stage Oncology Drug Market Size Overview by Clinical Development Status: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Clinical Development Status
7.2.1 Phase III Oncology Drugs
7.2.2 Registrational Oncology Drugs
7.2.3 Others
7.3 Market Segment by Clinical Development Status
7.3.1 World Late-Stage Oncology Drug Market Size by Clinical Development Status (2021-2026)
7.3.2 World Late-Stage Oncology Drug Market Size by Clinical Development Status (2027-2032)
7.3.3 World Late-Stage Oncology Drug Market Size Market Share by Clinical Development Status (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Late-Stage Oncology Drug Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Lung Cancer
8.2.2 Breast Cancer
8.2.3 Gastrointestinal Cancers
8.2.4 Genitourinary Cancers
8.2.5 Hematologic Malignancies
8.2.6 Gynecologic Cancers
8.2.7 Skin Cancer
8.2.8 Others
8.3 Market Segment by Application
8.3.1 World Late-Stage Oncology Drug Market Size by Application (2021-2026)
8.3.2 World Late-Stage Oncology Drug Market Size by Application (2027-2032)
8.3.3 World Late-Stage Oncology Drug Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Roche
9.1.1 Roche Details
9.1.2 Roche Major Business
9.1.3 Roche Late-Stage Oncology Drug Product and Services
9.1.4 Roche Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Roche Recent Developments/Updates
9.1.6 Roche Competitive Strengths & Weaknesses
9.2 Merck & Co.
9.2.1 Merck & Co. Details
9.2.2 Merck & Co. Major Business
9.2.3 Merck & Co. Late-Stage Oncology Drug Product and Services
9.2.4 Merck & Co. Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Merck & Co. Recent Developments/Updates
9.2.6 Merck & Co. Competitive Strengths & Weaknesses
9.3 Bristol Myers Squibb
9.3.1 Bristol Myers Squibb Details
9.3.2 Bristol Myers Squibb Major Business
9.3.3 Bristol Myers Squibb Late-Stage Oncology Drug Product and Services
9.3.4 Bristol Myers Squibb Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Bristol Myers Squibb Recent Developments/Updates
9.3.6 Bristol Myers Squibb Competitive Strengths & Weaknesses
9.4 Pfizer
9.4.1 Pfizer Details
9.4.2 Pfizer Major Business
9.4.3 Pfizer Late-Stage Oncology Drug Product and Services
9.4.4 Pfizer Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Pfizer Recent Developments/Updates
9.4.6 Pfizer Competitive Strengths & Weaknesses
9.5 Novartis
9.5.1 Novartis Details
9.5.2 Novartis Major Business
9.5.3 Novartis Late-Stage Oncology Drug Product and Services
9.5.4 Novartis Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Novartis Recent Developments/Updates
9.5.6 Novartis Competitive Strengths & Weaknesses
9.6 AstraZeneca
9.6.1 AstraZeneca Details
9.6.2 AstraZeneca Major Business
9.6.3 AstraZeneca Late-Stage Oncology Drug Product and Services
9.6.4 AstraZeneca Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 AstraZeneca Recent Developments/Updates
9.6.6 AstraZeneca Competitive Strengths & Weaknesses
9.7 Johnson & Johnson Innovative Medicine
9.7.1 Johnson & Johnson Innovative Medicine Details
9.7.2 Johnson & Johnson Innovative Medicine Major Business
9.7.3 Johnson & Johnson Innovative Medicine Late-Stage Oncology Drug Product and Services
9.7.4 Johnson & Johnson Innovative Medicine Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Johnson & Johnson Innovative Medicine Recent Developments/Updates
9.7.6 Johnson & Johnson Innovative Medicine Competitive Strengths & Weaknesses
9.8 Eli Lilly and Company
9.8.1 Eli Lilly and Company Details
9.8.2 Eli Lilly and Company Major Business
9.8.3 Eli Lilly and Company Late-Stage Oncology Drug Product and Services
9.8.4 Eli Lilly and Company Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Eli Lilly and Company Recent Developments/Updates
9.8.6 Eli Lilly and Company Competitive Strengths & Weaknesses
9.9 Sanofi
9.9.1 Sanofi Details
9.9.2 Sanofi Major Business
9.9.3 Sanofi Late-Stage Oncology Drug Product and Services
9.9.4 Sanofi Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Sanofi Recent Developments/Updates
9.9.6 Sanofi Competitive Strengths & Weaknesses
9.10 AbbVie
9.10.1 AbbVie Details
9.10.2 AbbVie Major Business
9.10.3 AbbVie Late-Stage Oncology Drug Product and Services
9.10.4 AbbVie Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 AbbVie Recent Developments/Updates
9.10.6 AbbVie Competitive Strengths & Weaknesses
9.11 GSK
9.11.1 GSK Details
9.11.2 GSK Major Business
9.11.3 GSK Late-Stage Oncology Drug Product and Services
9.11.4 GSK Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 GSK Recent Developments/Updates
9.11.6 GSK Competitive Strengths & Weaknesses
9.12 Amgen
9.12.1 Amgen Details
9.12.2 Amgen Major Business
9.12.3 Amgen Late-Stage Oncology Drug Product and Services
9.12.4 Amgen Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Amgen Recent Developments/Updates
9.12.6 Amgen Competitive Strengths & Weaknesses
9.13 Daiichi Sankyo Group
9.13.1 Daiichi Sankyo Group Details
9.13.2 Daiichi Sankyo Group Major Business
9.13.3 Daiichi Sankyo Group Late-Stage Oncology Drug Product and Services
9.13.4 Daiichi Sankyo Group Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Daiichi Sankyo Group Recent Developments/Updates
9.13.6 Daiichi Sankyo Group Competitive Strengths & Weaknesses
9.14 Takeda Pharmaceutical
9.14.1 Takeda Pharmaceutical Details
9.14.2 Takeda Pharmaceutical Major Business
9.14.3 Takeda Pharmaceutical Late-Stage Oncology Drug Product and Services
9.14.4 Takeda Pharmaceutical Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 Takeda Pharmaceutical Recent Developments/Updates
9.14.6 Takeda Pharmaceutical Competitive Strengths & Weaknesses
9.15 Astellas Pharma
9.15.1 Astellas Pharma Details
9.15.2 Astellas Pharma Major Business
9.15.3 Astellas Pharma Late-Stage Oncology Drug Product and Services
9.15.4 Astellas Pharma Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 Astellas Pharma Recent Developments/Updates
9.15.6 Astellas Pharma Competitive Strengths & Weaknesses
9.16 Eisai
9.16.1 Eisai Details
9.16.2 Eisai Major Business
9.16.3 Eisai Late-Stage Oncology Drug Product and Services
9.16.4 Eisai Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 Eisai Recent Developments/Updates
9.16.6 Eisai Competitive Strengths & Weaknesses
9.17 Taiho Pharmaceutical
9.17.1 Taiho Pharmaceutical Details
9.17.2 Taiho Pharmaceutical Major Business
9.17.3 Taiho Pharmaceutical Late-Stage Oncology Drug Product and Services
9.17.4 Taiho Pharmaceutical Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 Taiho Pharmaceutical Recent Developments/Updates
9.17.6 Taiho Pharmaceutical Competitive Strengths & Weaknesses
9.18 Ono Pharmaceutical
9.18.1 Ono Pharmaceutical Details
9.18.2 Ono Pharmaceutical Major Business
9.18.3 Ono Pharmaceutical Late-Stage Oncology Drug Product and Services
9.18.4 Ono Pharmaceutical Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 Ono Pharmaceutical Recent Developments/Updates
9.18.6 Ono Pharmaceutical Competitive Strengths & Weaknesses
9.19 Gilead Sciences
9.19.1 Gilead Sciences Details
9.19.2 Gilead Sciences Major Business
9.19.3 Gilead Sciences Late-Stage Oncology Drug Product and Services
9.19.4 Gilead Sciences Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.19.5 Gilead Sciences Recent Developments/Updates
9.19.6 Gilead Sciences Competitive Strengths & Weaknesses
9.20 Regeneron Pharmaceuticals
9.20.1 Regeneron Pharmaceuticals Details
9.20.2 Regeneron Pharmaceuticals Major Business
9.20.3 Regeneron Pharmaceuticals Late-Stage Oncology Drug Product and Services
9.20.4 Regeneron Pharmaceuticals Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.20.5 Regeneron Pharmaceuticals Recent Developments/Updates
9.20.6 Regeneron Pharmaceuticals Competitive Strengths & Weaknesses
9.21 Exelixis
9.21.1 Exelixis Details
9.21.2 Exelixis Major Business
9.21.3 Exelixis Late-Stage Oncology Drug Product and Services
9.21.4 Exelixis Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.21.5 Exelixis Recent Developments/Updates
9.21.6 Exelixis Competitive Strengths & Weaknesses
9.22 Incyte
9.22.1 Incyte Details
9.22.2 Incyte Major Business
9.22.3 Incyte Late-Stage Oncology Drug Product and Services
9.22.4 Incyte Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.22.5 Incyte Recent Developments/Updates
9.22.6 Incyte Competitive Strengths & Weaknesses
9.23 Ipsen
9.23.1 Ipsen Details
9.23.2 Ipsen Major Business
9.23.3 Ipsen Late-Stage Oncology Drug Product and Services
9.23.4 Ipsen Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.23.5 Ipsen Recent Developments/Updates
9.23.6 Ipsen Competitive Strengths & Weaknesses
9.24 AVEO Oncology
9.24.1 AVEO Oncology Details
9.24.2 AVEO Oncology Major Business
9.24.3 AVEO Oncology Late-Stage Oncology Drug Product and Services
9.24.4 AVEO Oncology Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.24.5 AVEO Oncology Recent Developments/Updates
9.24.6 AVEO Oncology Competitive Strengths & Weaknesses
9.25 BeOne Medicines
9.25.1 BeOne Medicines Details
9.25.2 BeOne Medicines Major Business
9.25.3 BeOne Medicines Late-Stage Oncology Drug Product and Services
9.25.4 BeOne Medicines Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.25.5 BeOne Medicines Recent Developments/Updates
9.25.6 BeOne Medicines Competitive Strengths & Weaknesses
9.26 Jiangsu Hengrui Pharmaceuticals
9.26.1 Jiangsu Hengrui Pharmaceuticals Details
9.26.2 Jiangsu Hengrui Pharmaceuticals Major Business
9.26.3 Jiangsu Hengrui Pharmaceuticals Late-Stage Oncology Drug Product and Services
9.26.4 Jiangsu Hengrui Pharmaceuticals Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.26.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
9.26.6 Jiangsu Hengrui Pharmaceuticals Competitive Strengths & Weaknesses
9.27 Innovent Biologics
9.27.1 Innovent Biologics Details
9.27.2 Innovent Biologics Major Business
9.27.3 Innovent Biologics Late-Stage Oncology Drug Product and Services
9.27.4 Innovent Biologics Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.27.5 Innovent Biologics Recent Developments/Updates
9.27.6 Innovent Biologics Competitive Strengths & Weaknesses
9.28 Shanghai Junshi Biosciences
9.28.1 Shanghai Junshi Biosciences Details
9.28.2 Shanghai Junshi Biosciences Major Business
9.28.3 Shanghai Junshi Biosciences Late-Stage Oncology Drug Product and Services
9.28.4 Shanghai Junshi Biosciences Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.28.5 Shanghai Junshi Biosciences Recent Developments/Updates
9.28.6 Shanghai Junshi Biosciences Competitive Strengths & Weaknesses
9.29 Akeso Biopharma
9.29.1 Akeso Biopharma Details
9.29.2 Akeso Biopharma Major Business
9.29.3 Akeso Biopharma Late-Stage Oncology Drug Product and Services
9.29.4 Akeso Biopharma Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.29.5 Akeso Biopharma Recent Developments/Updates
9.29.6 Akeso Biopharma Competitive Strengths & Weaknesses
9.30 Legend Biotech
9.30.1 Legend Biotech Details
9.30.2 Legend Biotech Major Business
9.30.3 Legend Biotech Late-Stage Oncology Drug Product and Services
9.30.4 Legend Biotech Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.30.5 Legend Biotech Recent Developments/Updates
9.30.6 Legend Biotech Competitive Strengths & Weaknesses
9.31 Zai Lab
9.31.1 Zai Lab Details
9.31.2 Zai Lab Major Business
9.31.3 Zai Lab Late-Stage Oncology Drug Product and Services
9.31.4 Zai Lab Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.31.5 Zai Lab Recent Developments/Updates
9.31.6 Zai Lab Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Late-Stage Oncology Drug Industry Chain
10.2 Late-Stage Oncology Drug Upstream Analysis
10.3 Late-Stage Oncology Drug Midstream Analysis
10.4 Late-Stage Oncology Drug Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Late-Stage Oncology Drug Introduction
1.2 World Late-Stage Oncology Drug Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Late-Stage Oncology Drug Total Market by Region (by Headquarter Location)
1.3.1 World Late-Stage Oncology Drug Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Late-Stage Oncology Drug Revenue (2021-2032)
1.3.3 China Based Company Late-Stage Oncology Drug Revenue (2021-2032)
1.3.4 Europe Based Company Late-Stage Oncology Drug Revenue (2021-2032)
1.3.5 Japan Based Company Late-Stage Oncology Drug Revenue (2021-2032)
1.3.6 South Korea Based Company Late-Stage Oncology Drug Revenue (2021-2032)
1.3.7 ASEAN Based Company Late-Stage Oncology Drug Revenue (2021-2032)
1.3.8 India Based Company Late-Stage Oncology Drug Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Late-Stage Oncology Drug Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Late-Stage Oncology Drug Consumption Value (2021-2032)
2.2 World Late-Stage Oncology Drug Consumption Value by Region
2.2.1 World Late-Stage Oncology Drug Consumption Value by Region (2021-2026)
2.2.2 World Late-Stage Oncology Drug Consumption Value Forecast by Region (2027-2032)
2.3 United States Late-Stage Oncology Drug Consumption Value (2021-2032)
2.4 China Late-Stage Oncology Drug Consumption Value (2021-2032)
2.5 Europe Late-Stage Oncology Drug Consumption Value (2021-2032)
2.6 Japan Late-Stage Oncology Drug Consumption Value (2021-2032)
2.7 South Korea Late-Stage Oncology Drug Consumption Value (2021-2032)
2.8 ASEAN Late-Stage Oncology Drug Consumption Value (2021-2032)
2.9 India Late-Stage Oncology Drug Consumption Value (2021-2032)
3 WORLD LATE-STAGE ONCOLOGY DRUG COMPANIES COMPETITIVE ANALYSIS
3.1 World Late-Stage Oncology Drug Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Late-Stage Oncology Drug Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Late-Stage Oncology Drug in 2025
3.2.3 Global Concentration Ratios (CR8) for Late-Stage Oncology Drug in 2025
3.3 Late-Stage Oncology Drug Company Evaluation Quadrant
3.4 Late-Stage Oncology Drug Market: Overall Company Footprint Analysis
3.4.1 Late-Stage Oncology Drug Market: Region Footprint
3.4.2 Late-Stage Oncology Drug Market: Company Product Type Footprint
3.4.3 Late-Stage Oncology Drug Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Late-Stage Oncology Drug Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Late-Stage Oncology Drug Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Late-Stage Oncology Drug Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Late-Stage Oncology Drug Consumption Value Comparison
4.2.1 United States VS China: Late-Stage Oncology Drug Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Late-Stage Oncology Drug Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Late-Stage Oncology Drug Companies and Market Share, 2021-2026
4.3.1 United States Based Late-Stage Oncology Drug Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Late-Stage Oncology Drug Revenue, (2021-2026)
4.4 China Based Companies Late-Stage Oncology Drug Revenue and Market Share, 2021-2026
4.4.1 China Based Late-Stage Oncology Drug Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Late-Stage Oncology Drug Revenue, (2021-2026)
4.5 Rest of World Based Late-Stage Oncology Drug Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Late-Stage Oncology Drug Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Late-Stage Oncology Drug Revenue (2021-2026)
5 MARKET ANALYSIS BY THERAPEUTIC MODALITY
5.1 World Late-Stage Oncology Drug Market Size Overview by Therapeutic Modality: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Therapeutic Modality
5.2.1 Small-Molecule Targeted Oncology Drugs
5.2.2 Monoclonal Antibody Oncology Drugs
5.2.3 Antibody-Drug Conjugates
5.2.4 Bispecific Antibody Oncology Drugs
5.2.5 Cell Therapy Oncology Drugs
5.2.6 Radioligand Oncology Drugs
5.2.7 Conventional Chemotherapy And Hormone Therapy Drugs
5.2.8 Others
5.3 Market Segment by Therapeutic Modality
5.3.1 World Late-Stage Oncology Drug Market Size by Therapeutic Modality (2021-2026)
5.3.2 World Late-Stage Oncology Drug Market Size by Therapeutic Modality (2027-2032)
5.3.3 World Late-Stage Oncology Drug Market Size Market Share by Therapeutic Modality (2027-2032)
6 MARKET ANALYSIS BY ANNUAL TREATMENT COST PER PATIENT
6.1 World Late-Stage Oncology Drug Market Size Overview by Annual Treatment Cost Per Patient: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Annual Treatment Cost Per Patient
6.2.1 Low-Priced Oncology Drugs: Below US$20,000 / Patient / Year
6.2.2 Mid-Priced Oncology Drugs: US$20,000?80,000 / Patient / Year
6.2.3 High-Priced Oncology Drugs: US$80,000?200,000 / Patient / Year
6.2.4 Ultra-High-Priced Oncology Drugs: Above US$200,000 / Patient / Year
6.3 Market Segment by Annual Treatment Cost Per Patient
6.3.1 World Late-Stage Oncology Drug Market Size by Annual Treatment Cost Per Patient (2021-2026)
6.3.2 World Late-Stage Oncology Drug Market Size by Annual Treatment Cost Per Patient (2027-2032)
6.3.3 World Late-Stage Oncology Drug Market Size Market Share by Annual Treatment Cost Per Patient (2027-2032)
7 MARKET ANALYSIS BY CLINICAL DEVELOPMENT STATUS
7.1 World Late-Stage Oncology Drug Market Size Overview by Clinical Development Status: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Clinical Development Status
7.2.1 Phase III Oncology Drugs
7.2.2 Registrational Oncology Drugs
7.2.3 Others
7.3 Market Segment by Clinical Development Status
7.3.1 World Late-Stage Oncology Drug Market Size by Clinical Development Status (2021-2026)
7.3.2 World Late-Stage Oncology Drug Market Size by Clinical Development Status (2027-2032)
7.3.3 World Late-Stage Oncology Drug Market Size Market Share by Clinical Development Status (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Late-Stage Oncology Drug Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Lung Cancer
8.2.2 Breast Cancer
8.2.3 Gastrointestinal Cancers
8.2.4 Genitourinary Cancers
8.2.5 Hematologic Malignancies
8.2.6 Gynecologic Cancers
8.2.7 Skin Cancer
8.2.8 Others
8.3 Market Segment by Application
8.3.1 World Late-Stage Oncology Drug Market Size by Application (2021-2026)
8.3.2 World Late-Stage Oncology Drug Market Size by Application (2027-2032)
8.3.3 World Late-Stage Oncology Drug Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Roche
9.1.1 Roche Details
9.1.2 Roche Major Business
9.1.3 Roche Late-Stage Oncology Drug Product and Services
9.1.4 Roche Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Roche Recent Developments/Updates
9.1.6 Roche Competitive Strengths & Weaknesses
9.2 Merck & Co.
9.2.1 Merck & Co. Details
9.2.2 Merck & Co. Major Business
9.2.3 Merck & Co. Late-Stage Oncology Drug Product and Services
9.2.4 Merck & Co. Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Merck & Co. Recent Developments/Updates
9.2.6 Merck & Co. Competitive Strengths & Weaknesses
9.3 Bristol Myers Squibb
9.3.1 Bristol Myers Squibb Details
9.3.2 Bristol Myers Squibb Major Business
9.3.3 Bristol Myers Squibb Late-Stage Oncology Drug Product and Services
9.3.4 Bristol Myers Squibb Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Bristol Myers Squibb Recent Developments/Updates
9.3.6 Bristol Myers Squibb Competitive Strengths & Weaknesses
9.4 Pfizer
9.4.1 Pfizer Details
9.4.2 Pfizer Major Business
9.4.3 Pfizer Late-Stage Oncology Drug Product and Services
9.4.4 Pfizer Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Pfizer Recent Developments/Updates
9.4.6 Pfizer Competitive Strengths & Weaknesses
9.5 Novartis
9.5.1 Novartis Details
9.5.2 Novartis Major Business
9.5.3 Novartis Late-Stage Oncology Drug Product and Services
9.5.4 Novartis Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Novartis Recent Developments/Updates
9.5.6 Novartis Competitive Strengths & Weaknesses
9.6 AstraZeneca
9.6.1 AstraZeneca Details
9.6.2 AstraZeneca Major Business
9.6.3 AstraZeneca Late-Stage Oncology Drug Product and Services
9.6.4 AstraZeneca Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 AstraZeneca Recent Developments/Updates
9.6.6 AstraZeneca Competitive Strengths & Weaknesses
9.7 Johnson & Johnson Innovative Medicine
9.7.1 Johnson & Johnson Innovative Medicine Details
9.7.2 Johnson & Johnson Innovative Medicine Major Business
9.7.3 Johnson & Johnson Innovative Medicine Late-Stage Oncology Drug Product and Services
9.7.4 Johnson & Johnson Innovative Medicine Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Johnson & Johnson Innovative Medicine Recent Developments/Updates
9.7.6 Johnson & Johnson Innovative Medicine Competitive Strengths & Weaknesses
9.8 Eli Lilly and Company
9.8.1 Eli Lilly and Company Details
9.8.2 Eli Lilly and Company Major Business
9.8.3 Eli Lilly and Company Late-Stage Oncology Drug Product and Services
9.8.4 Eli Lilly and Company Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Eli Lilly and Company Recent Developments/Updates
9.8.6 Eli Lilly and Company Competitive Strengths & Weaknesses
9.9 Sanofi
9.9.1 Sanofi Details
9.9.2 Sanofi Major Business
9.9.3 Sanofi Late-Stage Oncology Drug Product and Services
9.9.4 Sanofi Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Sanofi Recent Developments/Updates
9.9.6 Sanofi Competitive Strengths & Weaknesses
9.10 AbbVie
9.10.1 AbbVie Details
9.10.2 AbbVie Major Business
9.10.3 AbbVie Late-Stage Oncology Drug Product and Services
9.10.4 AbbVie Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 AbbVie Recent Developments/Updates
9.10.6 AbbVie Competitive Strengths & Weaknesses
9.11 GSK
9.11.1 GSK Details
9.11.2 GSK Major Business
9.11.3 GSK Late-Stage Oncology Drug Product and Services
9.11.4 GSK Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 GSK Recent Developments/Updates
9.11.6 GSK Competitive Strengths & Weaknesses
9.12 Amgen
9.12.1 Amgen Details
9.12.2 Amgen Major Business
9.12.3 Amgen Late-Stage Oncology Drug Product and Services
9.12.4 Amgen Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Amgen Recent Developments/Updates
9.12.6 Amgen Competitive Strengths & Weaknesses
9.13 Daiichi Sankyo Group
9.13.1 Daiichi Sankyo Group Details
9.13.2 Daiichi Sankyo Group Major Business
9.13.3 Daiichi Sankyo Group Late-Stage Oncology Drug Product and Services
9.13.4 Daiichi Sankyo Group Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Daiichi Sankyo Group Recent Developments/Updates
9.13.6 Daiichi Sankyo Group Competitive Strengths & Weaknesses
9.14 Takeda Pharmaceutical
9.14.1 Takeda Pharmaceutical Details
9.14.2 Takeda Pharmaceutical Major Business
9.14.3 Takeda Pharmaceutical Late-Stage Oncology Drug Product and Services
9.14.4 Takeda Pharmaceutical Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 Takeda Pharmaceutical Recent Developments/Updates
9.14.6 Takeda Pharmaceutical Competitive Strengths & Weaknesses
9.15 Astellas Pharma
9.15.1 Astellas Pharma Details
9.15.2 Astellas Pharma Major Business
9.15.3 Astellas Pharma Late-Stage Oncology Drug Product and Services
9.15.4 Astellas Pharma Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 Astellas Pharma Recent Developments/Updates
9.15.6 Astellas Pharma Competitive Strengths & Weaknesses
9.16 Eisai
9.16.1 Eisai Details
9.16.2 Eisai Major Business
9.16.3 Eisai Late-Stage Oncology Drug Product and Services
9.16.4 Eisai Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 Eisai Recent Developments/Updates
9.16.6 Eisai Competitive Strengths & Weaknesses
9.17 Taiho Pharmaceutical
9.17.1 Taiho Pharmaceutical Details
9.17.2 Taiho Pharmaceutical Major Business
9.17.3 Taiho Pharmaceutical Late-Stage Oncology Drug Product and Services
9.17.4 Taiho Pharmaceutical Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 Taiho Pharmaceutical Recent Developments/Updates
9.17.6 Taiho Pharmaceutical Competitive Strengths & Weaknesses
9.18 Ono Pharmaceutical
9.18.1 Ono Pharmaceutical Details
9.18.2 Ono Pharmaceutical Major Business
9.18.3 Ono Pharmaceutical Late-Stage Oncology Drug Product and Services
9.18.4 Ono Pharmaceutical Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 Ono Pharmaceutical Recent Developments/Updates
9.18.6 Ono Pharmaceutical Competitive Strengths & Weaknesses
9.19 Gilead Sciences
9.19.1 Gilead Sciences Details
9.19.2 Gilead Sciences Major Business
9.19.3 Gilead Sciences Late-Stage Oncology Drug Product and Services
9.19.4 Gilead Sciences Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.19.5 Gilead Sciences Recent Developments/Updates
9.19.6 Gilead Sciences Competitive Strengths & Weaknesses
9.20 Regeneron Pharmaceuticals
9.20.1 Regeneron Pharmaceuticals Details
9.20.2 Regeneron Pharmaceuticals Major Business
9.20.3 Regeneron Pharmaceuticals Late-Stage Oncology Drug Product and Services
9.20.4 Regeneron Pharmaceuticals Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.20.5 Regeneron Pharmaceuticals Recent Developments/Updates
9.20.6 Regeneron Pharmaceuticals Competitive Strengths & Weaknesses
9.21 Exelixis
9.21.1 Exelixis Details
9.21.2 Exelixis Major Business
9.21.3 Exelixis Late-Stage Oncology Drug Product and Services
9.21.4 Exelixis Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.21.5 Exelixis Recent Developments/Updates
9.21.6 Exelixis Competitive Strengths & Weaknesses
9.22 Incyte
9.22.1 Incyte Details
9.22.2 Incyte Major Business
9.22.3 Incyte Late-Stage Oncology Drug Product and Services
9.22.4 Incyte Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.22.5 Incyte Recent Developments/Updates
9.22.6 Incyte Competitive Strengths & Weaknesses
9.23 Ipsen
9.23.1 Ipsen Details
9.23.2 Ipsen Major Business
9.23.3 Ipsen Late-Stage Oncology Drug Product and Services
9.23.4 Ipsen Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.23.5 Ipsen Recent Developments/Updates
9.23.6 Ipsen Competitive Strengths & Weaknesses
9.24 AVEO Oncology
9.24.1 AVEO Oncology Details
9.24.2 AVEO Oncology Major Business
9.24.3 AVEO Oncology Late-Stage Oncology Drug Product and Services
9.24.4 AVEO Oncology Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.24.5 AVEO Oncology Recent Developments/Updates
9.24.6 AVEO Oncology Competitive Strengths & Weaknesses
9.25 BeOne Medicines
9.25.1 BeOne Medicines Details
9.25.2 BeOne Medicines Major Business
9.25.3 BeOne Medicines Late-Stage Oncology Drug Product and Services
9.25.4 BeOne Medicines Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.25.5 BeOne Medicines Recent Developments/Updates
9.25.6 BeOne Medicines Competitive Strengths & Weaknesses
9.26 Jiangsu Hengrui Pharmaceuticals
9.26.1 Jiangsu Hengrui Pharmaceuticals Details
9.26.2 Jiangsu Hengrui Pharmaceuticals Major Business
9.26.3 Jiangsu Hengrui Pharmaceuticals Late-Stage Oncology Drug Product and Services
9.26.4 Jiangsu Hengrui Pharmaceuticals Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.26.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
9.26.6 Jiangsu Hengrui Pharmaceuticals Competitive Strengths & Weaknesses
9.27 Innovent Biologics
9.27.1 Innovent Biologics Details
9.27.2 Innovent Biologics Major Business
9.27.3 Innovent Biologics Late-Stage Oncology Drug Product and Services
9.27.4 Innovent Biologics Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.27.5 Innovent Biologics Recent Developments/Updates
9.27.6 Innovent Biologics Competitive Strengths & Weaknesses
9.28 Shanghai Junshi Biosciences
9.28.1 Shanghai Junshi Biosciences Details
9.28.2 Shanghai Junshi Biosciences Major Business
9.28.3 Shanghai Junshi Biosciences Late-Stage Oncology Drug Product and Services
9.28.4 Shanghai Junshi Biosciences Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.28.5 Shanghai Junshi Biosciences Recent Developments/Updates
9.28.6 Shanghai Junshi Biosciences Competitive Strengths & Weaknesses
9.29 Akeso Biopharma
9.29.1 Akeso Biopharma Details
9.29.2 Akeso Biopharma Major Business
9.29.3 Akeso Biopharma Late-Stage Oncology Drug Product and Services
9.29.4 Akeso Biopharma Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.29.5 Akeso Biopharma Recent Developments/Updates
9.29.6 Akeso Biopharma Competitive Strengths & Weaknesses
9.30 Legend Biotech
9.30.1 Legend Biotech Details
9.30.2 Legend Biotech Major Business
9.30.3 Legend Biotech Late-Stage Oncology Drug Product and Services
9.30.4 Legend Biotech Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.30.5 Legend Biotech Recent Developments/Updates
9.30.6 Legend Biotech Competitive Strengths & Weaknesses
9.31 Zai Lab
9.31.1 Zai Lab Details
9.31.2 Zai Lab Major Business
9.31.3 Zai Lab Late-Stage Oncology Drug Product and Services
9.31.4 Zai Lab Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026)
9.31.5 Zai Lab Recent Developments/Updates
9.31.6 Zai Lab Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Late-Stage Oncology Drug Industry Chain
10.2 Late-Stage Oncology Drug Upstream Analysis
10.3 Late-Stage Oncology Drug Midstream Analysis
10.4 Late-Stage Oncology Drug Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Late-Stage Oncology Drug Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Late-Stage Oncology Drug Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Late-Stage Oncology Drug Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Late-Stage Oncology Drug Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Late-Stage Oncology Drug Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Late-Stage Oncology Drug Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Late-Stage Oncology Drug Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Late-Stage Oncology Drug Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Late-Stage Oncology Drug Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Late-Stage Oncology Drug Players in 2025
Table 12. World Late-Stage Oncology Drug Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Late-Stage Oncology Drug Company Evaluation Quadrant
Table 14. Head Office of Key Late-Stage Oncology Drug Players
Table 15. Late-Stage Oncology Drug Market: Company Product Type Footprint
Table 16. Late-Stage Oncology Drug Market: Company Product Application Footprint
Table 17. Late-Stage Oncology Drug Mergers & Acquisitions Activity
Table 18. United States VS China Late-Stage Oncology Drug Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Late-Stage Oncology Drug Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Late-Stage Oncology Drug Companies, Headquarters (States, Country)
Table 21. United States Based Companies Late-Stage Oncology Drug Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Late-Stage Oncology Drug Revenue Market Share (2021-2026)
Table 23. China Based Late-Stage Oncology Drug Companies, Headquarters (Province, Country)
Table 24. China Based Companies Late-Stage Oncology Drug Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Late-Stage Oncology Drug Revenue Market Share (2021-2026)
Table 26. Rest of World Based Late-Stage Oncology Drug Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Late-Stage Oncology Drug Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Late-Stage Oncology Drug Revenue Market Share (2021-2026)
Table 29. World Late-Stage Oncology Drug Market Size by Therapeutic Modality, (USD Million), 2021 & 2025 & 2032
Table 30. World Late-Stage Oncology Drug Market Size Value by Therapeutic Modality (2021-2026) & (USD Million)
Table 31. World Late-Stage Oncology Drug Market Size by Therapeutic Modality (2027-2032) & (USD Million)
Table 32. World Late-Stage Oncology Drug Market Size by Annual Treatment Cost Per Patient, (USD Million), 2021 & 2025 & 2032
Table 33. World Late-Stage Oncology Drug Market Size Value by Annual Treatment Cost Per Patient (2021-2026) & (USD Million)
Table 34. World Late-Stage Oncology Drug Market Size by Annual Treatment Cost Per Patient (2027-2032) & (USD Million)
Table 35. World Late-Stage Oncology Drug Market Size by Clinical Development Status, (USD Million), 2021 & 2025 & 2032
Table 36. World Late-Stage Oncology Drug Market Size Value by Clinical Development Status (2021-2026) & (USD Million)
Table 37. World Late-Stage Oncology Drug Market Size by Clinical Development Status (2027-2032) & (USD Million)
Table 38. World Late-Stage Oncology Drug Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Late-Stage Oncology Drug Market Size by Application (2021-2026) & (USD Million)
Table 40. World Late-Stage Oncology Drug Market Size by Application (2027-2032) & (USD Million)
Table 41. Roche Basic Information, Manufacturing Base and Competitors
Table 42. Roche Major Business
Table 43. Roche Late-Stage Oncology Drug Product and Services
Table 44. Roche Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Roche Recent Developments/Updates
Table 46. Roche Competitive Strengths & Weaknesses
Table 47. Merck & Co. Basic Information, Manufacturing Base and Competitors
Table 48. Merck & Co. Major Business
Table 49. Merck & Co. Late-Stage Oncology Drug Product and Services
Table 50. Merck & Co. Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Merck & Co. Recent Developments/Updates
Table 52. Merck & Co. Competitive Strengths & Weaknesses
Table 53. Bristol Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 54. Bristol Myers Squibb Major Business
Table 55. Bristol Myers Squibb Late-Stage Oncology Drug Product and Services
Table 56. Bristol Myers Squibb Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Bristol Myers Squibb Recent Developments/Updates
Table 58. Bristol Myers Squibb Competitive Strengths & Weaknesses
Table 59. Pfizer Basic Information, Manufacturing Base and Competitors
Table 60. Pfizer Major Business
Table 61. Pfizer Late-Stage Oncology Drug Product and Services
Table 62. Pfizer Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Pfizer Recent Developments/Updates
Table 64. Pfizer Competitive Strengths & Weaknesses
Table 65. Novartis Basic Information, Manufacturing Base and Competitors
Table 66. Novartis Major Business
Table 67. Novartis Late-Stage Oncology Drug Product and Services
Table 68. Novartis Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Novartis Recent Developments/Updates
Table 70. Novartis Competitive Strengths & Weaknesses
Table 71. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 72. AstraZeneca Major Business
Table 73. AstraZeneca Late-Stage Oncology Drug Product and Services
Table 74. AstraZeneca Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. AstraZeneca Recent Developments/Updates
Table 76. AstraZeneca Competitive Strengths & Weaknesses
Table 77. Johnson & Johnson Innovative Medicine Basic Information, Manufacturing Base and Competitors
Table 78. Johnson & Johnson Innovative Medicine Major Business
Table 79. Johnson & Johnson Innovative Medicine Late-Stage Oncology Drug Product and Services
Table 80. Johnson & Johnson Innovative Medicine Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Johnson & Johnson Innovative Medicine Recent Developments/Updates
Table 82. Johnson & Johnson Innovative Medicine Competitive Strengths & Weaknesses
Table 83. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 84. Eli Lilly and Company Major Business
Table 85. Eli Lilly and Company Late-Stage Oncology Drug Product and Services
Table 86. Eli Lilly and Company Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Eli Lilly and Company Recent Developments/Updates
Table 88. Eli Lilly and Company Competitive Strengths & Weaknesses
Table 89. Sanofi Basic Information, Manufacturing Base and Competitors
Table 90. Sanofi Major Business
Table 91. Sanofi Late-Stage Oncology Drug Product and Services
Table 92. Sanofi Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Sanofi Recent Developments/Updates
Table 94. Sanofi Competitive Strengths & Weaknesses
Table 95. AbbVie Basic Information, Manufacturing Base and Competitors
Table 96. AbbVie Major Business
Table 97. AbbVie Late-Stage Oncology Drug Product and Services
Table 98. AbbVie Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. AbbVie Recent Developments/Updates
Table 100. AbbVie Competitive Strengths & Weaknesses
Table 101. GSK Basic Information, Manufacturing Base and Competitors
Table 102. GSK Major Business
Table 103. GSK Late-Stage Oncology Drug Product and Services
Table 104. GSK Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. GSK Recent Developments/Updates
Table 106. GSK Competitive Strengths & Weaknesses
Table 107. Amgen Basic Information, Manufacturing Base and Competitors
Table 108. Amgen Major Business
Table 109. Amgen Late-Stage Oncology Drug Product and Services
Table 110. Amgen Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Amgen Recent Developments/Updates
Table 112. Amgen Competitive Strengths & Weaknesses
Table 113. Daiichi Sankyo Group Basic Information, Manufacturing Base and Competitors
Table 114. Daiichi Sankyo Group Major Business
Table 115. Daiichi Sankyo Group Late-Stage Oncology Drug Product and Services
Table 116. Daiichi Sankyo Group Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Daiichi Sankyo Group Recent Developments/Updates
Table 118. Daiichi Sankyo Group Competitive Strengths & Weaknesses
Table 119. Takeda Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 120. Takeda Pharmaceutical Major Business
Table 121. Takeda Pharmaceutical Late-Stage Oncology Drug Product and Services
Table 122. Takeda Pharmaceutical Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. Takeda Pharmaceutical Recent Developments/Updates
Table 124. Takeda Pharmaceutical Competitive Strengths & Weaknesses
Table 125. Astellas Pharma Basic Information, Manufacturing Base and Competitors
Table 126. Astellas Pharma Major Business
Table 127. Astellas Pharma Late-Stage Oncology Drug Product and Services
Table 128. Astellas Pharma Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. Astellas Pharma Recent Developments/Updates
Table 130. Astellas Pharma Competitive Strengths & Weaknesses
Table 131. Eisai Basic Information, Manufacturing Base and Competitors
Table 132. Eisai Major Business
Table 133. Eisai Late-Stage Oncology Drug Product and Services
Table 134. Eisai Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. Eisai Recent Developments/Updates
Table 136. Eisai Competitive Strengths & Weaknesses
Table 137. Taiho Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 138. Taiho Pharmaceutical Major Business
Table 139. Taiho Pharmaceutical Late-Stage Oncology Drug Product and Services
Table 140. Taiho Pharmaceutical Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. Taiho Pharmaceutical Recent Developments/Updates
Table 142. Taiho Pharmaceutical Competitive Strengths & Weaknesses
Table 143. Ono Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 144. Ono Pharmaceutical Major Business
Table 145. Ono Pharmaceutical Late-Stage Oncology Drug Product and Services
Table 146. Ono Pharmaceutical Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. Ono Pharmaceutical Recent Developments/Updates
Table 148. Ono Pharmaceutical Competitive Strengths & Weaknesses
Table 149. Gilead Sciences Basic Information, Manufacturing Base and Competitors
Table 150. Gilead Sciences Major Business
Table 151. Gilead Sciences Late-Stage Oncology Drug Product and Services
Table 152. Gilead Sciences Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. Gilead Sciences Recent Developments/Updates
Table 154. Gilead Sciences Competitive Strengths & Weaknesses
Table 155. Regeneron Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 156. Regeneron Pharmaceuticals Major Business
Table 157. Regeneron Pharmaceuticals Late-Stage Oncology Drug Product and Services
Table 158. Regeneron Pharmaceuticals Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. Regeneron Pharmaceuticals Recent Developments/Updates
Table 160. Regeneron Pharmaceuticals Competitive Strengths & Weaknesses
Table 161. Exelixis Basic Information, Manufacturing Base and Competitors
Table 162. Exelixis Major Business
Table 163. Exelixis Late-Stage Oncology Drug Product and Services
Table 164. Exelixis Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 165. Exelixis Recent Developments/Updates
Table 166. Exelixis Competitive Strengths & Weaknesses
Table 167. Incyte Basic Information, Manufacturing Base and Competitors
Table 168. Incyte Major Business
Table 169. Incyte Late-Stage Oncology Drug Product and Services
Table 170. Incyte Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 171. Incyte Recent Developments/Updates
Table 172. Incyte Competitive Strengths & Weaknesses
Table 173. Ipsen Basic Information, Manufacturing Base and Competitors
Table 174. Ipsen Major Business
Table 175. Ipsen Late-Stage Oncology Drug Product and Services
Table 176. Ipsen Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 177. Ipsen Recent Developments/Updates
Table 178. Ipsen Competitive Strengths & Weaknesses
Table 179. AVEO Oncology Basic Information, Manufacturing Base and Competitors
Table 180. AVEO Oncology Major Business
Table 181. AVEO Oncology Late-Stage Oncology Drug Product and Services
Table 182. AVEO Oncology Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 183. AVEO Oncology Recent Developments/Updates
Table 184. AVEO Oncology Competitive Strengths & Weaknesses
Table 185. BeOne Medicines Basic Information, Manufacturing Base and Competitors
Table 186. BeOne Medicines Major Business
Table 187. BeOne Medicines Late-Stage Oncology Drug Product and Services
Table 188. BeOne Medicines Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 189. BeOne Medicines Recent Developments/Updates
Table 190. BeOne Medicines Competitive Strengths & Weaknesses
Table 191. Jiangsu Hengrui Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 192. Jiangsu Hengrui Pharmaceuticals Major Business
Table 193. Jiangsu Hengrui Pharmaceuticals Late-Stage Oncology Drug Product and Services
Table 194. Jiangsu Hengrui Pharmaceuticals Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 195. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 196. Jiangsu Hengrui Pharmaceuticals Competitive Strengths & Weaknesses
Table 197. Innovent Biologics Basic Information, Manufacturing Base and Competitors
Table 198. Innovent Biologics Major Business
Table 199. Innovent Biologics Late-Stage Oncology Drug Product and Services
Table 200. Innovent Biologics Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 201. Innovent Biologics Recent Developments/Updates
Table 202. Innovent Biologics Competitive Strengths & Weaknesses
Table 203. Shanghai Junshi Biosciences Basic Information, Manufacturing Base and Competitors
Table 204. Shanghai Junshi Biosciences Major Business
Table 205. Shanghai Junshi Biosciences Late-Stage Oncology Drug Product and Services
Table 206. Shanghai Junshi Biosciences Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 207. Shanghai Junshi Biosciences Recent Developments/Updates
Table 208. Shanghai Junshi Biosciences Competitive Strengths & Weaknesses
Table 209. Akeso Biopharma Basic Information, Manufacturing Base and Competitors
Table 210. Akeso Biopharma Major Business
Table 211. Akeso Biopharma Late-Stage Oncology Drug Product and Services
Table 212. Akeso Biopharma Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 213. Akeso Biopharma Recent Developments/Updates
Table 214. Akeso Biopharma Competitive Strengths & Weaknesses
Table 215. Legend Biotech Basic Information, Manufacturing Base and Competitors
Table 216. Legend Biotech Major Business
Table 217. Legend Biotech Late-Stage Oncology Drug Product and Services
Table 218. Legend Biotech Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 219. Legend Biotech Recent Developments/Updates
Table 220. Legend Biotech Competitive Strengths & Weaknesses
Table 221. Zai Lab Basic Information, Manufacturing Base and Competitors
Table 222. Zai Lab Major Business
Table 223. Zai Lab Late-Stage Oncology Drug Product and Services
Table 224. Zai Lab Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 225. Zai Lab Recent Developments/Updates
Table 226. Zai Lab Competitive Strengths & Weaknesses
Table 227. Global Key Players of Late-Stage Oncology Drug Upstream (Raw Materials)
Table 228. Global Late-Stage Oncology Drug Typical Customers
Table 1. World Late-Stage Oncology Drug Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Late-Stage Oncology Drug Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Late-Stage Oncology Drug Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Late-Stage Oncology Drug Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Late-Stage Oncology Drug Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Late-Stage Oncology Drug Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Late-Stage Oncology Drug Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Late-Stage Oncology Drug Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Late-Stage Oncology Drug Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Late-Stage Oncology Drug Players in 2025
Table 12. World Late-Stage Oncology Drug Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Late-Stage Oncology Drug Company Evaluation Quadrant
Table 14. Head Office of Key Late-Stage Oncology Drug Players
Table 15. Late-Stage Oncology Drug Market: Company Product Type Footprint
Table 16. Late-Stage Oncology Drug Market: Company Product Application Footprint
Table 17. Late-Stage Oncology Drug Mergers & Acquisitions Activity
Table 18. United States VS China Late-Stage Oncology Drug Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Late-Stage Oncology Drug Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Late-Stage Oncology Drug Companies, Headquarters (States, Country)
Table 21. United States Based Companies Late-Stage Oncology Drug Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Late-Stage Oncology Drug Revenue Market Share (2021-2026)
Table 23. China Based Late-Stage Oncology Drug Companies, Headquarters (Province, Country)
Table 24. China Based Companies Late-Stage Oncology Drug Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Late-Stage Oncology Drug Revenue Market Share (2021-2026)
Table 26. Rest of World Based Late-Stage Oncology Drug Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Late-Stage Oncology Drug Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Late-Stage Oncology Drug Revenue Market Share (2021-2026)
Table 29. World Late-Stage Oncology Drug Market Size by Therapeutic Modality, (USD Million), 2021 & 2025 & 2032
Table 30. World Late-Stage Oncology Drug Market Size Value by Therapeutic Modality (2021-2026) & (USD Million)
Table 31. World Late-Stage Oncology Drug Market Size by Therapeutic Modality (2027-2032) & (USD Million)
Table 32. World Late-Stage Oncology Drug Market Size by Annual Treatment Cost Per Patient, (USD Million), 2021 & 2025 & 2032
Table 33. World Late-Stage Oncology Drug Market Size Value by Annual Treatment Cost Per Patient (2021-2026) & (USD Million)
Table 34. World Late-Stage Oncology Drug Market Size by Annual Treatment Cost Per Patient (2027-2032) & (USD Million)
Table 35. World Late-Stage Oncology Drug Market Size by Clinical Development Status, (USD Million), 2021 & 2025 & 2032
Table 36. World Late-Stage Oncology Drug Market Size Value by Clinical Development Status (2021-2026) & (USD Million)
Table 37. World Late-Stage Oncology Drug Market Size by Clinical Development Status (2027-2032) & (USD Million)
Table 38. World Late-Stage Oncology Drug Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Late-Stage Oncology Drug Market Size by Application (2021-2026) & (USD Million)
Table 40. World Late-Stage Oncology Drug Market Size by Application (2027-2032) & (USD Million)
Table 41. Roche Basic Information, Manufacturing Base and Competitors
Table 42. Roche Major Business
Table 43. Roche Late-Stage Oncology Drug Product and Services
Table 44. Roche Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Roche Recent Developments/Updates
Table 46. Roche Competitive Strengths & Weaknesses
Table 47. Merck & Co. Basic Information, Manufacturing Base and Competitors
Table 48. Merck & Co. Major Business
Table 49. Merck & Co. Late-Stage Oncology Drug Product and Services
Table 50. Merck & Co. Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Merck & Co. Recent Developments/Updates
Table 52. Merck & Co. Competitive Strengths & Weaknesses
Table 53. Bristol Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 54. Bristol Myers Squibb Major Business
Table 55. Bristol Myers Squibb Late-Stage Oncology Drug Product and Services
Table 56. Bristol Myers Squibb Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Bristol Myers Squibb Recent Developments/Updates
Table 58. Bristol Myers Squibb Competitive Strengths & Weaknesses
Table 59. Pfizer Basic Information, Manufacturing Base and Competitors
Table 60. Pfizer Major Business
Table 61. Pfizer Late-Stage Oncology Drug Product and Services
Table 62. Pfizer Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Pfizer Recent Developments/Updates
Table 64. Pfizer Competitive Strengths & Weaknesses
Table 65. Novartis Basic Information, Manufacturing Base and Competitors
Table 66. Novartis Major Business
Table 67. Novartis Late-Stage Oncology Drug Product and Services
Table 68. Novartis Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Novartis Recent Developments/Updates
Table 70. Novartis Competitive Strengths & Weaknesses
Table 71. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 72. AstraZeneca Major Business
Table 73. AstraZeneca Late-Stage Oncology Drug Product and Services
Table 74. AstraZeneca Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. AstraZeneca Recent Developments/Updates
Table 76. AstraZeneca Competitive Strengths & Weaknesses
Table 77. Johnson & Johnson Innovative Medicine Basic Information, Manufacturing Base and Competitors
Table 78. Johnson & Johnson Innovative Medicine Major Business
Table 79. Johnson & Johnson Innovative Medicine Late-Stage Oncology Drug Product and Services
Table 80. Johnson & Johnson Innovative Medicine Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Johnson & Johnson Innovative Medicine Recent Developments/Updates
Table 82. Johnson & Johnson Innovative Medicine Competitive Strengths & Weaknesses
Table 83. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 84. Eli Lilly and Company Major Business
Table 85. Eli Lilly and Company Late-Stage Oncology Drug Product and Services
Table 86. Eli Lilly and Company Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Eli Lilly and Company Recent Developments/Updates
Table 88. Eli Lilly and Company Competitive Strengths & Weaknesses
Table 89. Sanofi Basic Information, Manufacturing Base and Competitors
Table 90. Sanofi Major Business
Table 91. Sanofi Late-Stage Oncology Drug Product and Services
Table 92. Sanofi Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Sanofi Recent Developments/Updates
Table 94. Sanofi Competitive Strengths & Weaknesses
Table 95. AbbVie Basic Information, Manufacturing Base and Competitors
Table 96. AbbVie Major Business
Table 97. AbbVie Late-Stage Oncology Drug Product and Services
Table 98. AbbVie Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. AbbVie Recent Developments/Updates
Table 100. AbbVie Competitive Strengths & Weaknesses
Table 101. GSK Basic Information, Manufacturing Base and Competitors
Table 102. GSK Major Business
Table 103. GSK Late-Stage Oncology Drug Product and Services
Table 104. GSK Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. GSK Recent Developments/Updates
Table 106. GSK Competitive Strengths & Weaknesses
Table 107. Amgen Basic Information, Manufacturing Base and Competitors
Table 108. Amgen Major Business
Table 109. Amgen Late-Stage Oncology Drug Product and Services
Table 110. Amgen Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Amgen Recent Developments/Updates
Table 112. Amgen Competitive Strengths & Weaknesses
Table 113. Daiichi Sankyo Group Basic Information, Manufacturing Base and Competitors
Table 114. Daiichi Sankyo Group Major Business
Table 115. Daiichi Sankyo Group Late-Stage Oncology Drug Product and Services
Table 116. Daiichi Sankyo Group Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Daiichi Sankyo Group Recent Developments/Updates
Table 118. Daiichi Sankyo Group Competitive Strengths & Weaknesses
Table 119. Takeda Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 120. Takeda Pharmaceutical Major Business
Table 121. Takeda Pharmaceutical Late-Stage Oncology Drug Product and Services
Table 122. Takeda Pharmaceutical Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. Takeda Pharmaceutical Recent Developments/Updates
Table 124. Takeda Pharmaceutical Competitive Strengths & Weaknesses
Table 125. Astellas Pharma Basic Information, Manufacturing Base and Competitors
Table 126. Astellas Pharma Major Business
Table 127. Astellas Pharma Late-Stage Oncology Drug Product and Services
Table 128. Astellas Pharma Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. Astellas Pharma Recent Developments/Updates
Table 130. Astellas Pharma Competitive Strengths & Weaknesses
Table 131. Eisai Basic Information, Manufacturing Base and Competitors
Table 132. Eisai Major Business
Table 133. Eisai Late-Stage Oncology Drug Product and Services
Table 134. Eisai Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. Eisai Recent Developments/Updates
Table 136. Eisai Competitive Strengths & Weaknesses
Table 137. Taiho Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 138. Taiho Pharmaceutical Major Business
Table 139. Taiho Pharmaceutical Late-Stage Oncology Drug Product and Services
Table 140. Taiho Pharmaceutical Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. Taiho Pharmaceutical Recent Developments/Updates
Table 142. Taiho Pharmaceutical Competitive Strengths & Weaknesses
Table 143. Ono Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 144. Ono Pharmaceutical Major Business
Table 145. Ono Pharmaceutical Late-Stage Oncology Drug Product and Services
Table 146. Ono Pharmaceutical Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. Ono Pharmaceutical Recent Developments/Updates
Table 148. Ono Pharmaceutical Competitive Strengths & Weaknesses
Table 149. Gilead Sciences Basic Information, Manufacturing Base and Competitors
Table 150. Gilead Sciences Major Business
Table 151. Gilead Sciences Late-Stage Oncology Drug Product and Services
Table 152. Gilead Sciences Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. Gilead Sciences Recent Developments/Updates
Table 154. Gilead Sciences Competitive Strengths & Weaknesses
Table 155. Regeneron Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 156. Regeneron Pharmaceuticals Major Business
Table 157. Regeneron Pharmaceuticals Late-Stage Oncology Drug Product and Services
Table 158. Regeneron Pharmaceuticals Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. Regeneron Pharmaceuticals Recent Developments/Updates
Table 160. Regeneron Pharmaceuticals Competitive Strengths & Weaknesses
Table 161. Exelixis Basic Information, Manufacturing Base and Competitors
Table 162. Exelixis Major Business
Table 163. Exelixis Late-Stage Oncology Drug Product and Services
Table 164. Exelixis Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 165. Exelixis Recent Developments/Updates
Table 166. Exelixis Competitive Strengths & Weaknesses
Table 167. Incyte Basic Information, Manufacturing Base and Competitors
Table 168. Incyte Major Business
Table 169. Incyte Late-Stage Oncology Drug Product and Services
Table 170. Incyte Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 171. Incyte Recent Developments/Updates
Table 172. Incyte Competitive Strengths & Weaknesses
Table 173. Ipsen Basic Information, Manufacturing Base and Competitors
Table 174. Ipsen Major Business
Table 175. Ipsen Late-Stage Oncology Drug Product and Services
Table 176. Ipsen Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 177. Ipsen Recent Developments/Updates
Table 178. Ipsen Competitive Strengths & Weaknesses
Table 179. AVEO Oncology Basic Information, Manufacturing Base and Competitors
Table 180. AVEO Oncology Major Business
Table 181. AVEO Oncology Late-Stage Oncology Drug Product and Services
Table 182. AVEO Oncology Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 183. AVEO Oncology Recent Developments/Updates
Table 184. AVEO Oncology Competitive Strengths & Weaknesses
Table 185. BeOne Medicines Basic Information, Manufacturing Base and Competitors
Table 186. BeOne Medicines Major Business
Table 187. BeOne Medicines Late-Stage Oncology Drug Product and Services
Table 188. BeOne Medicines Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 189. BeOne Medicines Recent Developments/Updates
Table 190. BeOne Medicines Competitive Strengths & Weaknesses
Table 191. Jiangsu Hengrui Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 192. Jiangsu Hengrui Pharmaceuticals Major Business
Table 193. Jiangsu Hengrui Pharmaceuticals Late-Stage Oncology Drug Product and Services
Table 194. Jiangsu Hengrui Pharmaceuticals Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 195. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 196. Jiangsu Hengrui Pharmaceuticals Competitive Strengths & Weaknesses
Table 197. Innovent Biologics Basic Information, Manufacturing Base and Competitors
Table 198. Innovent Biologics Major Business
Table 199. Innovent Biologics Late-Stage Oncology Drug Product and Services
Table 200. Innovent Biologics Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 201. Innovent Biologics Recent Developments/Updates
Table 202. Innovent Biologics Competitive Strengths & Weaknesses
Table 203. Shanghai Junshi Biosciences Basic Information, Manufacturing Base and Competitors
Table 204. Shanghai Junshi Biosciences Major Business
Table 205. Shanghai Junshi Biosciences Late-Stage Oncology Drug Product and Services
Table 206. Shanghai Junshi Biosciences Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 207. Shanghai Junshi Biosciences Recent Developments/Updates
Table 208. Shanghai Junshi Biosciences Competitive Strengths & Weaknesses
Table 209. Akeso Biopharma Basic Information, Manufacturing Base and Competitors
Table 210. Akeso Biopharma Major Business
Table 211. Akeso Biopharma Late-Stage Oncology Drug Product and Services
Table 212. Akeso Biopharma Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 213. Akeso Biopharma Recent Developments/Updates
Table 214. Akeso Biopharma Competitive Strengths & Weaknesses
Table 215. Legend Biotech Basic Information, Manufacturing Base and Competitors
Table 216. Legend Biotech Major Business
Table 217. Legend Biotech Late-Stage Oncology Drug Product and Services
Table 218. Legend Biotech Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 219. Legend Biotech Recent Developments/Updates
Table 220. Legend Biotech Competitive Strengths & Weaknesses
Table 221. Zai Lab Basic Information, Manufacturing Base and Competitors
Table 222. Zai Lab Major Business
Table 223. Zai Lab Late-Stage Oncology Drug Product and Services
Table 224. Zai Lab Late-Stage Oncology Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 225. Zai Lab Recent Developments/Updates
Table 226. Zai Lab Competitive Strengths & Weaknesses
Table 227. Global Key Players of Late-Stage Oncology Drug Upstream (Raw Materials)
Table 228. Global Late-Stage Oncology Drug Typical Customers
LIST OF FIGURES
Figure 1. Late-Stage Oncology Drug Picture
Figure 2. World Late-Stage Oncology Drug Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Late-Stage Oncology Drug Total Revenue (2021-2032) & (USD Million)
Figure 4. World Late-Stage Oncology Drug Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Late-Stage Oncology Drug Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Late-Stage Oncology Drug Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Late-Stage Oncology Drug Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Late-Stage Oncology Drug Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Late-Stage Oncology Drug Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Late-Stage Oncology Drug Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Late-Stage Oncology Drug Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Late-Stage Oncology Drug Revenue (2021-2032) & (USD Million)
Figure 13. Late-Stage Oncology Drug Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Late-Stage Oncology Drug Consumption Value (2021-2032) & (USD Million)
Figure 16. World Late-Stage Oncology Drug Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Late-Stage Oncology Drug Consumption Value (2021-2032) & (USD Million)
Figure 18. China Late-Stage Oncology Drug Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Late-Stage Oncology Drug Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Late-Stage Oncology Drug Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Late-Stage Oncology Drug Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Late-Stage Oncology Drug Consumption Value (2021-2032) & (USD Million)
Figure 23. India Late-Stage Oncology Drug Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Late-Stage Oncology Drug by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Late-Stage Oncology Drug Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Late-Stage Oncology Drug Markets in 2025
Figure 27. United States VS China: Late-Stage Oncology Drug Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Late-Stage Oncology Drug Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Late-Stage Oncology Drug Market Size by Therapeutic Modality, (USD Million), 2021 & 2025 & 2032
Figure 30. World Late-Stage Oncology Drug Market Size Market Share by Therapeutic Modality in 2025
Figure 31. Small-Molecule Targeted Oncology Drugs
Figure 32. Monoclonal Antibody Oncology Drugs
Figure 33. Antibody-Drug Conjugates
Figure 34. Bispecific Antibody Oncology Drugs
Figure 35. Cell Therapy Oncology Drugs
Figure 36. Radioligand Oncology Drugs
Figure 37. Conventional Chemotherapy And Hormone Therapy Drugs
Figure 38. Others
Figure 39. Conventional Chemotherapy And Hormone Therapy Drugs
Figure 40. World Late-Stage Oncology Drug Market Size Market Share by Therapeutic Modality (2021-2032)
Figure 41. World Late-Stage Oncology Drug Market Size by Annual Treatment Cost Per Patient, (USD Million), 2021 & 2025 & 2032
Figure 42. World Late-Stage Oncology Drug Market Size Market Share by Annual Treatment Cost Per Patient in 2025
Figure 43. Low-Priced Oncology Drugs: Below US$20,000 / Patient / Year
Figure 44. Mid-Priced Oncology Drugs: US$20,000?80,000 / Patient / Year
Figure 45. High-Priced Oncology Drugs: US$80,000?200,000 / Patient / Year
Figure 46. Ultra-High-Priced Oncology Drugs: Above US$200,000 / Patient / Year
Figure 47. World Late-Stage Oncology Drug Market Size Market Share by Annual Treatment Cost Per Patient (2021-2032)
Figure 48. World Late-Stage Oncology Drug Market Size by Clinical Development Status, (USD Million), 2021 & 2025 & 2032
Figure 49. World Late-Stage Oncology Drug Market Size Market Share by Clinical Development Status in 2025
Figure 50. Phase III Oncology Drugs
Figure 51. Registrational Oncology Drugs
Figure 52. Others
Figure 53. World Late-Stage Oncology Drug Market Size Market Share by Clinical Development Status (2021-2032)
Figure 54. World Late-Stage Oncology Drug Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 55. World Late-Stage Oncology Drug Market Size Market Share by Application in 2025
Figure 56. Lung Cancer
Figure 57. Breast Cancer
Figure 58. Gastrointestinal Cancers
Figure 59. Genitourinary Cancers
Figure 60. Hematologic Malignancies
Figure 61. Gynecologic Cancers
Figure 62. Skin Cancer
Figure 63. Others
Figure 64. Others
Figure 65. World Late-Stage Oncology Drug Market Size Market Share by Application (2021-2032)
Figure 66. Late-Stage Oncology Drug Industrial Chain
Figure 67. Methodology
Figure 68. Research Process and Data Source
Figure 1. Late-Stage Oncology Drug Picture
Figure 2. World Late-Stage Oncology Drug Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Late-Stage Oncology Drug Total Revenue (2021-2032) & (USD Million)
Figure 4. World Late-Stage Oncology Drug Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Late-Stage Oncology Drug Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Late-Stage Oncology Drug Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Late-Stage Oncology Drug Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Late-Stage Oncology Drug Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Late-Stage Oncology Drug Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Late-Stage Oncology Drug Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Late-Stage Oncology Drug Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Late-Stage Oncology Drug Revenue (2021-2032) & (USD Million)
Figure 13. Late-Stage Oncology Drug Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Late-Stage Oncology Drug Consumption Value (2021-2032) & (USD Million)
Figure 16. World Late-Stage Oncology Drug Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Late-Stage Oncology Drug Consumption Value (2021-2032) & (USD Million)
Figure 18. China Late-Stage Oncology Drug Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Late-Stage Oncology Drug Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Late-Stage Oncology Drug Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Late-Stage Oncology Drug Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Late-Stage Oncology Drug Consumption Value (2021-2032) & (USD Million)
Figure 23. India Late-Stage Oncology Drug Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Late-Stage Oncology Drug by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Late-Stage Oncology Drug Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Late-Stage Oncology Drug Markets in 2025
Figure 27. United States VS China: Late-Stage Oncology Drug Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Late-Stage Oncology Drug Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Late-Stage Oncology Drug Market Size by Therapeutic Modality, (USD Million), 2021 & 2025 & 2032
Figure 30. World Late-Stage Oncology Drug Market Size Market Share by Therapeutic Modality in 2025
Figure 31. Small-Molecule Targeted Oncology Drugs
Figure 32. Monoclonal Antibody Oncology Drugs
Figure 33. Antibody-Drug Conjugates
Figure 34. Bispecific Antibody Oncology Drugs
Figure 35. Cell Therapy Oncology Drugs
Figure 36. Radioligand Oncology Drugs
Figure 37. Conventional Chemotherapy And Hormone Therapy Drugs
Figure 38. Others
Figure 39. Conventional Chemotherapy And Hormone Therapy Drugs
Figure 40. World Late-Stage Oncology Drug Market Size Market Share by Therapeutic Modality (2021-2032)
Figure 41. World Late-Stage Oncology Drug Market Size by Annual Treatment Cost Per Patient, (USD Million), 2021 & 2025 & 2032
Figure 42. World Late-Stage Oncology Drug Market Size Market Share by Annual Treatment Cost Per Patient in 2025
Figure 43. Low-Priced Oncology Drugs: Below US$20,000 / Patient / Year
Figure 44. Mid-Priced Oncology Drugs: US$20,000?80,000 / Patient / Year
Figure 45. High-Priced Oncology Drugs: US$80,000?200,000 / Patient / Year
Figure 46. Ultra-High-Priced Oncology Drugs: Above US$200,000 / Patient / Year
Figure 47. World Late-Stage Oncology Drug Market Size Market Share by Annual Treatment Cost Per Patient (2021-2032)
Figure 48. World Late-Stage Oncology Drug Market Size by Clinical Development Status, (USD Million), 2021 & 2025 & 2032
Figure 49. World Late-Stage Oncology Drug Market Size Market Share by Clinical Development Status in 2025
Figure 50. Phase III Oncology Drugs
Figure 51. Registrational Oncology Drugs
Figure 52. Others
Figure 53. World Late-Stage Oncology Drug Market Size Market Share by Clinical Development Status (2021-2032)
Figure 54. World Late-Stage Oncology Drug Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 55. World Late-Stage Oncology Drug Market Size Market Share by Application in 2025
Figure 56. Lung Cancer
Figure 57. Breast Cancer
Figure 58. Gastrointestinal Cancers
Figure 59. Genitourinary Cancers
Figure 60. Hematologic Malignancies
Figure 61. Gynecologic Cancers
Figure 62. Skin Cancer
Figure 63. Others
Figure 64. Others
Figure 65. World Late-Stage Oncology Drug Market Size Market Share by Application (2021-2032)
Figure 66. Late-Stage Oncology Drug Industrial Chain
Figure 67. Methodology
Figure 68. Research Process and Data Source
